進行性血液がん患者における単回経口投与後の[14C]-DSP-5336の吸収、分解、および体内からの除去の仕組み
難治性または再発性急性白血病、骨髄異形成症候群、多発性骨髄腫、または骨髄増殖性腫瘍患者における単回経口投与後のDSP-5336の吸収、代謝、排泄に関する第1相オープンラベル試験
The purpose of this study is to evaluate the absorption, metabolism, and excretion of DSP-5336 following a single oral administration of the study drug in patients with hematologic malignancies whose disease has progressed after available standard therapies.
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
North Carolina
-
Chapel Hill、North Carolina、アメリカ、27514
- University of North Carolina
-
-
Texas
-
Houston、Texas、アメリカ、77030
- MD Anderson Cancer Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Male or female, of any race, ≥ 18 years of age. Female patients must be surgically sterile or postmenopausal. Male patients must be permanently sterile or agree to use contraception.
- Have an advanced hematological malignancy that is relapsed, refractory, or has progressed following receipt of standard and available treatments.
- Any prior pre-treatment toxicities resolved to ≤Grade 1 prior to enrolment, with exception of ≤Grade 2 alopecia or neuropathy.
- Adequate kidney and liver function
- ECOG performance status of ≤ 2.
- Able to attend the required study visits, including the confinement period for monitoring and collection of bowel movements and micturition.
- Able to comprehend and are willing to sign the ICF and abide by the study restrictions.
Exclusion Criteria:
- Histologic diagnosis of acute promyelocytic leukemia.
- Abnormal ECG that is clinically significant, such as QTcF > 480 msec. QT interval correction can be performed in the case of bundle branch block.
- History of torsades de pointes.
- Left ventricular ejection fraction ≤ 45%, as determined by echocardiogram.
- Have any concurrent conditions that could pose an undue risk or interfere with interpretation of the study results, including, but not limited to clinically significant non-healing or healing wounds, concurrent congestive heart failure, unstable angina, cardiac arrhythmia requiring treatment (excluding asymptomatic atrial fibrillation), myocardial infarction within 6 months, acute coronary syndrome within 6 months, significant pulmonary disease (shortness of breath at rest or on mild exertion; eg, due to concurrent severe obstructive pulmonary disease, hypertension not controlled with concomitant medication, or diabetes mellitus with > 2 episodes of ketoacidosis in the prior 6 months).
- History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy and hernia repair are allowed).
- History or evidence of severe dysphagia, short-gut syndrome, gastroparesis, gastrointestinal tract disease, malabsorption syndrome, the requirement for intravenous alimentation, gastric/jejunal feeds, any uncontrolled gastrointestinal disease, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally, including the inability to swallow oral medication
- Have cognitive, psychological, or psychosocial impediment that would impair their ability to receive therapy according to the protocol or would adversely affect their ability to comply with the informed consent process, protocol, or protocol-required visits and procedures.
- History of bowel obstruction, abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months of check-in, unless approved by the investigator and medical monitor.
- Active and uncontrolled bacterial, viral, or fungal infection requiring parenteral therapy.
- Positive hepatitis panel and/or positive human immunodeficiency virus test indicative of active infection. Patients whose results are compatible with prior immunization may be included.
- Undergone HSCT, chimeric antigen receptor cell therapy, or other modified T-cell therapy within 60 days prior to dosing.
- Received donor lymphocyte infusion within 28 days prior to dosing, receiving immunosuppressive therapy post-HSCT, or have clinically active GVHD or GVHD requiring active medical intervention other than the use of topical steroids for ongoing cutaneous GVHD.
- Received systemic calcineurin inhibitors within 2 weeks prior to dosing.
- Received other anticancer drugs or other investigational treatment within 14 days or 5 half-lives, whichever is shorter, prior to dosing.
- Major surgery within 28 days prior to dosing.
- Any known intolerance or hypersensitivity to components of the study intervention.
- Patients who have previously been dosed in > 2 radiolabeled drug studies in the last 12 months. For patients who have previously been dosed in ≤ 2 radiolabeled drug studies within the last 12 months, the previous radiolabeled dose must be at least 4 months prior to check-in to the study site where exposures are known to the investigator or 6 months prior to check-in to the study site for a radiolabeled drug study where exposures are not known to the investigator.
- Poor peripheral venous access.
- Patients with exposure to significant diagnostic or therapeutic radiation or current employment in a job requiring radiation exposure monitoring within 12 months prior to check-in.
- Patients who, in the opinion of the investigator or designee, should not participate in this study.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:DSP-5336 tablets and [14C]-DSP-5336 solution
Part 1 |
tablet oral solution |
|
実験的:Optional Continued Access
Part 2 |
tablet |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Total recovery of radioactivity in urine as percentage of total radioactive dose of [14C]-DSP-5336
時間枠:Day 1 to 4, max 7 days if less than 90% is collected by Day 4
|
The percentage of dose excreted in urine |
Day 1 to 4, max 7 days if less than 90% is collected by Day 4
|
|
Total recovery of radioactivity in fecal waste as percentage of total radioactive dose of [14C]-DSP-5336
時間枠:Day 1 to 4, max 7 days if less than 90% is collected by Day 4
|
The percentage of dose excreted in fecal waste |
Day 1 to 4, max 7 days if less than 90% is collected by Day 4
|
|
Total recovery of radioactivity in excreta balance as percentage of total radioactive dose of [14C]-DSP-5336
時間枠:Day 1 to 4, max 7 days if less than 90% is collected by Day 4
|
The percentage of dose excreted in combined urine and fecal waste |
Day 1 to 4, max 7 days if less than 90% is collected by Day 4
|
|
Relative abundance (mean value) of [14C]-DSP-5336
時間枠:4 days, max 7 days
|
Plasma samples will be analyzed for [14C]-DSP-5336 and its metabolites. |
4 days, max 7 days
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Area under the plasma concentration time profile from time zero to time of the last quantifiable concentration (AUClast) of [14C]-DSP-5336
時間枠:4 days, max 7 days
|
The determination of AUClast using the linear/log trapezoidal rule |
4 days, max 7 days
|
|
Cmax for the relative bioavailability of [14C]-DSP-5336
時間枠:4 days, max 7 days
|
Analysis of the maximum concentration (Cmax) of the relative bioavailability of [14C]-DSP-5336 utilizing the ratio of the adjusted geometric means |
4 days, max 7 days
|
|
t(1/2) of [14C]-DSP-5336
時間枠:4 days, max 7 days
|
Elimination half-life (t[1/2]) of [14C]-DSP-5336 |
4 days, max 7 days
|
|
Ratio of plasma to whole blood total radioactivity
時間枠:4 days, max 7 days
|
The fraction of [14C]-DSP-5336 radioactivity associated with whole blood and plasma and with red blood cells and other cellular components of whole blood was determined by using the concentration of [14C]-DSP-5336 radioactivity in whole blood and plasma |
4 days, max 7 days
|
|
Number of participants with adverse events and serious adverse events
時間枠:30 days
|
Safety of DSP-5336 by reporting of AEs and SAEs |
30 days
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- DSP-5336-102
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。